TG Therapeutics (NasdaqCM:TGTX) FY Conference January 13, 2026 04:30 PM ET Company ParticipantsMichael Weiss - CEOConference Call ParticipantsBrian Cheng - Senior Biotech AnalystBrian ChengGood afternoon, everyone. Thanks for joining us for another session at the 44th J.P. Morgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. On stage, we have Mike Weiss, who is the CEO of TG Therapeutics. I'll now pass the mic to their CEO for a short presentation, followed ...

Summary of Bitfarms Conference Call Company Overview - **Company**: Bitfarms - **Industry**: Data Center Infrastructure and Cryptocurrency Mining Key Points and Arguments Market Thesis - Bitfarms believes the demand for high-performance computing (HPC) and AI infrastructure is not a bubble but a new paradigm with over 20 years of exponential growth at an annualized rate of 8.8% [6][7] - The demand for data center capacity is accelerating due to AI, but the growth in data center infrastructure is lagging behind, leading to increased lease rates from an average of 3% over the last 20 years to 12% since 2022 [7][10] Infrastructure Bottlenecks - The real bottleneck for growth in HPC and AI is power and infrastructure, not silicon or capital [8] - A predicted shortfall of nearly 45 gigawatts of power for data centers by 2030 has been confirmed by industry leaders [10] Strategic Actions - Bitfarms plans to prioritize infrastructure development to minimize the time between signing leases and generating revenue [11] - The company aims to lock in higher rates and margins under multi-year agreements due to the widening gap between supply and demand for data center infrastructure [12] - Bitfarms intends to lead in developing infrastructure for NVIDIA's next-generation Vera Rubin GPUs, expected to be in high demand by 2027 [12] Energy Portfolio - Bitfarms has the largest portfolio of power in its operational regions, with all power being 100% renewable [13][16] - The company has secured 170 megawatts in Quebec, which represents a unique opportunity to increase total data center megawatts in the province by 25% [16][17] Site-Specific Developments - **Panther Creek**: 350 megawatts of secured power, with potential expansion beyond 410 megawatts [22] - **Sharon**: 110 megawatts of power secured, with full capacity expected by the end of 2026 [23] - **Quebec**: 170 megawatts of low-cost hydropower, with plans to convert Bitcoin mining infrastructure to HPC and AI [24] - **Scrubgrass**: Potential for over 1 gigawatt of capacity, with ongoing evaluations for additional generating capacity [27][28] Financial Position - Bitfarms has $750 million of unencumbered liquidity and $200 million available for project development [34] - The company generates approximately $8 million a month from Bitcoin operations, which funds operational expenses and capital investments [34] Future Outlook - The company expects to reach Notice to Proceed (NTP) for Washington, Sharon, and Panther Creek by the end of 2026, which will allow for lease negotiations and revenue generation [38][53] - Bitfarms is exploring a potential cloud monetization strategy for its Washington site, which could provide significant cash flow [30][60] Risks and Considerations - The company emphasizes the importance of maintaining a strong balance sheet to avoid over-leverage and ensure sustainable growth [39][42] - Bitfarms is cautious about speculative investments and focuses on securing high-quality sites for development [62][68] Additional Important Content - The company is actively receiving inquiries for its facilities, particularly in Sharon and Moses Lake, indicating strong market interest [45][46] - Bitfarms is committed to maximizing shareholder value while balancing lease pricing and development timelines [52][53]

TETRA Technologies (NYSE:TTI) FY Conference Summary Company Overview - TETRA Technologies is currently on a run rate of approximately $600 million in revenue and over $100 million in EBITDA, with EBITDA margins steadily increasing over the years, reaching 33% recently [1][3] - The company has divested from compression, offshore oil and gas, and decommissioning businesses to focus on water and flowback services and industrial chemicals in offshore oil and gas completion fluids [2] Financial Performance - Revenue for the trailing 12 months ended September was $362 million, the highest in a decade [3] - EBITDA margins have historically been in the mid- to high 20s, with a recent increase to 33% due to significant deep water wells completed in the Gulf of Mexico [3] - The calcium chloride business generated about $160 million in revenue with 30% EBITDA margins, which is not correlated to oil and gas [3] Strategic Focus and Growth Initiatives - TETRA is transitioning into sectors with higher growth opportunities beyond oil and gas, including battery storage and water treatment [5][14] - The company has seen a significant ramp-up in sales of a zinc bromide-based solution to EOS, increasing from $3 million in 2024 to approximately $20 million in 2025, with expectations of $50-$60 million in 2026 [5][6] - TETRA is developing technologies for water desalination and purification, targeting applications in crop irrigation and data center cooling [6][22] Market Dynamics and Competitive Position - TETRA is expanding its operations to extract bromine from the Smackover Formation in Arkansas to meet increasing demand from EOS and the offshore oil and gas market [7][27] - The company competes with larger firms like Schlumberger, Halliburton, and Baker Hughes, but maintains a market share of up to 30% due to its vertically integrated business model and unique chemistry know-how [11] Future Projections - TETRA aims to grow revenue from $600 million to $1.25 billion and EBITDA from over $100 million to about $325 million by 2030, with a balanced revenue mix from oil and gas, water treatment, and specialty chemicals [13][14] - The company plans to treat 500,000 barrels of produced water per day by 2030, translating to over $400 million in revenue and over $100 million in EBITDA [35] Operational Insights - TETRA's water treatment model involves cleaning produced water for beneficial reuse, with a focus on meeting the specifications required for data center operations [22][40] - The company has a solid balance sheet with a leverage ratio of 1.2 times and $50-$60 million in cash, positioning it well for future investments [28][29] Conclusion - TETRA Technologies is strategically repositioning itself to capitalize on high-growth markets in battery storage and water treatment while maintaining strong margins in its traditional oil and gas business, which is expected to create significant shareholder value [29][50]

Summary of The Real Brokerage FY Conference Call Company Overview - **Company Name**: The Real Brokerage (NasdaqCM:REAX) - **Industry**: Real Estate Technology - **Founded**: 2014 - **Current Revenue**: Expected to exceed $2 billion in 2023, up from approximately $300 million in 2022, representing a growth of about 7x in two to three years [4][5] Core Business Model - **Agent Monetization**: Revenue is generated through commission splits with agents and additional fees. The company has diversified its revenue streams by entering mortgage, title, and fintech products [4][5]. - **Agent Acquisition**: 100% organic growth, with 85% of new agents coming from referrals and 15% from inbound inquiries. The company does not spend on upfront marketing costs [10][11]. - **Agent Churn**: The company experiences a 7% quarterly churn rate among agents, but revenue churn from productive agents is significantly lower at 1.4% [16][17]. Competitive Advantages - **Value Proposition**: Offers agents more freedom, flexibility, and lower costs compared to traditional brokerages. Agents pay about half of what they would at traditional firms [6][7]. - **Technology Suite**: Provides a comprehensive operating system for agents, including marketing and productivity tools [7][8]. - **Collaborative Culture**: Focuses on collaboration rather than competition among agents, fostering a unique company culture [8]. Recent Developments - **AI Integration**: Launched "Leo," an AI assistant that handles support tickets and will soon engage with clients directly, enhancing agent productivity and client interaction [20][25]. - **New Features**: Leo will assist agents in nurturing leads and pre-qualifying clients for mortgages, potentially increasing transaction volumes [25][26]. - **Attach Rates**: The company is working on increasing attach rates for its mortgage and title services, currently at 1% and 4% respectively, with joint ventures showing over 30% attach rates [82][88]. Market Outlook - **Housing Market Predictions**: Anticipates around 4.3 million homes sold in 2026, with a gradual recovery expected as affordability improves and demand is unlocked [54][61]. - **Interest Rates**: Low mortgage rates in the low fives are seen as a potential catalyst for market recovery [62][64]. Strategic Focus for 2026 - **Growth Goals**: Aims to continue adding agents and increasing transaction counts while focusing on high-margin services such as title and mortgage [119]. - **Operational Efficiency**: Plans to reduce operating expenses per transaction through technology and scale, which will enhance profitability [115][116]. Additional Insights - **Private Label Program**: Allows small independent brokerages to operate under Real's umbrella while maintaining their branding, contributing to 15% of growth [12][13]. - **Agent Engagement**: The company is focused on keeping agents engaged through various monetization opportunities, including a share purchase program and referral incentives [17][96]. This summary encapsulates the key points discussed during the conference call, highlighting the company's growth trajectory, competitive advantages, and strategic initiatives moving forward.

HeartFlow (NasdaqGS:HTFL) FY Conference Summary Company Overview - HeartFlow is a software company utilizing AI for the treatment, diagnosis, and management of coronary artery disease, founded in 2010 with FDA clearance in 2014 [1][2] - The company targets the symptomatic market, estimating a total addressable market (TAM) of $5 billion [2] Key Financial Performance - In 2025, HeartFlow added 340 new accounts, reaching a total of 1,465 accounts, marking the best fiscal year for account additions [2] - Trailing 12 months revenue reached $162 million, reflecting a 41% growth [3] - Strong Q4 performance with no negative surprises, exceeding consensus expectations [3][4] Product and Technology Developments - HeartFlow has developed the world's largest proprietary database of coronary CCTA images, with over 160 million annotated images [3] - The company is expanding its product offerings with plaque analysis, currently live in 489 accounts, with a goal of over 1,000 accounts by the end of 2026 [4][26] - New randomized controlled trials (RCTs) will be initiated in 2026 to expand into the asymptomatic market [4][34] Clinical Evidence and Market Position - HeartFlow has over 600 peer-reviewed publications supporting its clinical evidence [3] - The company aims to create a new standard of care in coronary artery disease, currently having less than 2% market penetration [9][32] - The company’s AI-driven approach is compared to advancements in cancer diagnostics, emphasizing improved accuracy and patient outcomes [8][9] Growth Strategy - HeartFlow's strategy involves starting with the most diseased patients and gradually moving to less urgent cases, including asymptomatic patients [9][34] - The company plans to leverage its existing technology to enter the asymptomatic market, targeting a TAM of $6 billion [34] Market Dynamics and Competition - HeartFlow faces competition from the current standard of care, which is deemed inaccurate [5][32] - The company is focused on educating the market and driving adoption of its plaque analysis technology [40][42] Financial Outlook - HeartFlow aims for profitability within three years post-IPO, targeting 2028 for cash flow break-even [47] - The company expects continued revenue growth driven by its subscription model and expansion into new markets [48] Coverage and Reimbursement - Over 70% of lives are covered for plaque analysis, with a Category I CPT code in place [13][28] - The company is actively working with payers to expand coverage based on clinical data from its DECIDE registry [27][43] Conclusion - HeartFlow is positioned for significant growth with a strong focus on clinical evidence, market education, and expanding its product offerings in the coronary artery disease space [37][48]

GoodRx FY Conference Summary Company Overview - **Company**: GoodRx (NasdaqGS:GDRX) - **Date of Conference**: January 13, 2026 - **Speakers**: CEO Wendy Barnes, CFO Chris McGinnis, and Lisa Gill from JPMorgan Key Industry Dynamics - **Health Benefits Landscape**: Significant changes are occurring, including reductions in ACA subsidies, changes to Medicaid coverage, and an increase in high-deductible plans, which are leading to higher uninsured and underinsured rates [4][5] - **Consumer Behavior**: The trend of underinsurance is pushing more consumers to utilize cash for prescriptions, with approximately 90% of GoodRx users having insurance but still facing high out-of-pocket costs for medications [6] Core Business Insights - **Drug Affordability**: The current administration's focus on drug affordability aligns with GoodRx's mission, although the effectiveness of policy changes remains uncertain [9][10] - **Retail Pharmacy Challenges**: Retail pharmacies are facing closures and margin pressures, prompting GoodRx to partner directly with retailers to enhance their profitability and efficiency [11][12] - **Script Recapture Strategy**: GoodRx aims to recapture scripts from closed pharmacies like Rite Aid, estimating a potential recovery of 20%-40% of those scripts over time [19][21] Subscription Services - **Condition-Based Offerings**: GoodRx launched subscription services for conditions like ED, hair loss, and weight loss in 2025, focusing on branded therapies and competitive pricing [22][25] - **Market Potential**: The company sees significant opportunities in condition subscriptions, particularly in areas where traditional insurance coverage is limited [27] Manufacturer Solutions - **Growth in Manufacturer Solutions**: This segment has grown over 40% year-over-year, driven by manufacturers rethinking their commercial strategies and seeking partnerships with GoodRx to reach consumers effectively [29][30] - **Regulatory Environment**: The favorable regulatory landscape is encouraging manufacturers to engage in direct-to-consumer strategies, enhancing GoodRx's appeal as a partner [32] New Strategic Partnership - **Partnership with Surescripts**: GoodRx announced a partnership with Surescripts to launch "Script Corner," a tool aimed at providing price transparency to patients at the point of prescription [42][43] - **Impact on Patient Care**: The initiative aims to reduce prescription abandonment by providing patients with upfront pricing information, thereby improving adherence to prescribed therapies [55][61] Financial Outlook - **EBITDA Margins**: GoodRx is focused on maintaining cost discipline and expanding EBITDA margins, with potential variability based on strategic investments in marketing and partnerships [38][39] - **Future Guidance**: Specific financial guidance for 2026 will be provided later, but the company is optimistic about its growth trajectory [26][70] Conclusion - **Investor Understanding**: GoodRx aims to clarify its revenue model, emphasizing the integration of manufacturer solutions with its Rx marketplace and the potential for partnerships at the employer level [69][70] - **Commitment to Transparency**: The company is dedicated to enhancing transparency in drug pricing and improving consumer access to affordable medications [58][62]

Veeva Systems FY Conference Summary Company Overview - **Company**: Veeva Systems (NYSE: VEEV) - **Industry**: Life Sciences Software and Consulting - **Market Opportunity**: Approximately $20 billion market with 16% penetration, indicating significant growth potential [6][7] Core Business Model and Vision - **Vision**: To build the industry cloud for life sciences, integrating software, data, and consulting to enhance efficiency across R&D, manufacturing, and commercial sectors [3][6] - **Values**: Emphasis on integrity, customer success, employee success, and speed [4][5] - **Public Benefit Corporation**: Veeva is the first public company to convert to a Public Benefit Corporation, balancing the interests of shareholders, customers, employees, and society [6] Product Portfolio - **Product Suites**: Veeva offers over 10 product suites and more than 50 products, categorized into: - Development Cloud: Clinical, regulatory, and safety management - Quality Cloud: Manufacturing quality assurance - Commercial Cloud: Sales, medical, and marketing solutions - Data Cloud: Data management and analytics [7][9] - **Unique Selling Proposition**: The "suite effect" allows customers to benefit from interconnected products, reducing integration complexities [10][11] Market Dynamics and Trends - **AI Integration**: AI is becoming integral in life sciences, enhancing productivity in drug discovery and clinical trials [17][18] - **Industry Connectivity**: Increased collaboration among stakeholders, leading to faster and more inclusive clinical trials [18] - **Changing Commercial Models**: Shift towards ongoing care and precision medicine as standard practice [18] Financial Performance and Growth Strategy - **Revenue Growth**: Expected revenue of $3.17 billion for the current fiscal year, representing a 15% growth rate [30] - **Long-term Goals**: Targeting $6 billion in revenue by 2030, implying a 13% annual growth rate [27] - **Investment Focus**: Significant investment in product development, with a commitment to maintaining high operating margins (expected 45% non-GAAP) [30][31] Competitive Landscape - **Main Competitors**: Salesforce in CRM and Medidata in clinical areas, with many competitors being niche providers [36][37] - **Market Share**: Veeva holds over 80% market share in biopharma CRM, expecting to maintain over 70% post-migration to Vault CRM [23][24] Capital Allocation and M&A Strategy - **Cash Position**: Over $6.5 billion in cash with no debt, allowing for both M&A and shareholder returns [32][33] - **Share Repurchase Program**: Announced a $2 billion share repurchase over two years to return value to shareholders [33] - **M&A Focus**: Targeting strategic acquisitions to enhance product excellence and expand into cross-industry software [39][40] Customer Engagement and Consulting - **Customer Success**: Veeva's products are designed to be mission-critical, leading to high customer retention and advocacy [14][45] - **Business Consulting**: Growing segment focused on helping customers optimize business processes and implement technology effectively [50][51] Crossix Business Insights - **Digital Marketing Growth**: Crossix continues to show strong growth in digital marketing and measurement, with potential to match CRM size in the future [52][54] - **Market Leadership Potential**: Positioned to gain further market share in a growing digital marketing landscape [53][54] Profitability and Margin Management - **Profitability Strategy**: Focus on sustainable growth without artificial margin targets, allowing for necessary investments in innovation [55][56] - **Operating Leverage**: Anticipated improvements in margins as Salesforce royalties decline and investments in AI and data products yield returns [56] This summary encapsulates the key points from the Veeva Systems FY Conference, highlighting the company's strategic vision, product offerings, market dynamics, financial performance, and future growth opportunities.

Cellectar Biosciences (NasdaqCM:CLRB) 2026 Conference January 13, 2026 04:30 PM ET Company ParticipantsJim Caruso - CEOModeratorYeah. No, the cubs. Cubs. Who are you talking about? Good afternoon. Welcome back to session. My name is Matt Gardner. I'll be your moderator for this afternoon. Our first presenting company in the afternoon session is Cellectar Biosciences from Florham Park, New Jersey. As a Westfield guy, I have great pride introducing you here, Jim. Cellectar is focused on oncology, platform tec ...

Ciena (NYSE:CIEN) FY Conference Summary Company Overview - **Company**: Ciena Corporation - **Industry**: Communications and Networking - **Conference Date**: January 13, 2026 Key Points Financial Performance - Ciena initially guided for 8%-11% growth but achieved a remarkable 19% growth in revenue for the year [7][8] - The company reported $7.8 billion in orders and over $4.8 billion in revenue, ending the year with a backlog exceeding $5 billion [49] Drivers of Growth - The primary driver of growth was attributed to AI, with significant demand from cloud providers, including hyperscalers and new entrants known as NeoScalers [7][8] - The optical systems business saw over 20% growth, with a notable increase in market share, reaching over 30% globally (excluding China) [10][28] Market Dynamics - There is a hyper-competitive environment among cloud providers, leading to unprecedented demand for connectivity infrastructure to support AI training clusters [8][12] - Ciena's cloud customer base grew over 50% year-over-year, with expectations of 70% growth in hyperscale CapEx in 2025 [11] Product Innovations - Ciena has successfully entered the pluggable transceiver market, achieving approximately 15% market share and doubling its business to just under $170 million [19] - The introduction of the 800ZR pluggable transceiver is expected to significantly impact production volume and profitability in 2026 [20] Managed Optical Fiber Networks (MOFN) - MOFN is a growing segment, with over 30 MOFN WANs globally, and it grew about 150% year-over-year in 2025 [30][34] - This segment is expected to approach 50% of Ciena's revenues when combined with direct data center interconnect business [34] New Technologies and Applications - Ciena is developing MultiRail technology to densify existing optical amplifier architecture, which could represent a multi-billion dollar opportunity [66] - The company is also focusing on coherent optics for data centers, anticipating a shift from IMDD to coherent technology as data rates increase [69] Supply Chain and Operational Efficiency - Ciena is facing supply chain challenges, particularly with specialized optical components, but is actively working to address these issues [50][81] - The company has guided for flat operating expenses year-over-year despite significant revenue growth, indicating operational efficiencies and strategic reallocations [90][91] Competitive Landscape - Ciena competes with major players like Nokia, Infinera, and Cisco, with a focus on maintaining a strong position in the optical systems market [96] - The competitive landscape is evolving, with potential consolidation among NeoScalers and ongoing investments in technology and infrastructure [60] Future Outlook - Ciena expects continued growth driven by AI and cloud infrastructure, with a projected CapEx growth rate of 20% among hyperscalers and NeoScalers through the end of the decade [60] - The company aims for mid-40s gross margin as a waypoint in the coming years, despite current headwinds from production ramp-up and input pricing [84] M&A Strategy - Ciena has a history of strategic acquisitions, such as Nubis, to bolster its core business and fill technology gaps [101] Conclusion Ciena is positioned for significant growth driven by AI and cloud demand, with a strong focus on innovation in optical technologies and strategic market positioning. The company is navigating supply chain challenges while maintaining operational efficiency and exploring new market opportunities.

Five9 FY Conference Summary Company Overview - **Company**: Five9 (NasdaqGM:FIVN) - **Industry**: Cloud-based Customer Experience (CX) Software - **Revenue Growth**: From $10 million in 2008 to approximately $1.1-$1.2 billion in 2025, indicating significant growth over the years [5][9] Key Points and Arguments Leadership Transition - **Outgoing CEO**: Mike Burkland will step down but remain as Executive Chair [11] - **Incoming CEO**: Amit Mathradas, noted for his experience in AI and automation, will take over on February 2, 2026 [21][23] Business Model and Growth Drivers - **Core Business**: Five9's traditional CCaaS (Contact Center as a Service) is projected to grow at a 9% CAGR, with 60% of contact centers still using on-premise solutions [24] - **AI Growth**: AI-driven CX is expected to grow at a 34% CAGR, with Five9's AI revenue growing by 41% in the last quarter [24][25] - **Market Opportunity**: The total addressable market (TAM) for contact centers is $24 billion, with only 40% penetration, indicating substantial growth potential [26] Competitive Advantages - **End-to-End Platform**: Five9's integrated platform allows for seamless orchestration of customer interactions, providing a competitive edge over point solutions [34][40] - **Conversational Data**: The platform serves as a system of record for conversational data, enhancing AI capabilities and personalization [40][41] Customer Engagement and Adoption - **AI as a Catalyst**: AI is driving customers to transition from on-premise to cloud solutions, with many enterprises considering AI-first strategies [26][28] - **Large Deals**: Five9 has secured significant contracts with major brands like Wells Fargo, CVS, and FedEx, attributed to its reliable and scalable platform [31][32] Financial Metrics - **Net Revenue Retention (NRR)**: Slight decline from 108% to 107% due to tough comparisons and seasonality, but expected to improve in 2026 with a backlog of new bookings [51][53] - **Profitability Goals**: Targeting a midterm adjusted EBITDA margin of 25%-30% by 2027, driven by operational efficiencies and a growing AI portfolio [55][56] Pricing Strategy - **Consumption-Based Pricing**: Transitioning to interaction-based contracts, allowing flexibility between human and AI interactions [46][47] - **Annual Invoicing**: Moving towards annual invoicing for larger customers to improve cash flow and working capital efficiency [58] Additional Insights - **AI Development**: Five9 employs an engine-agnostic strategy for AI, allowing integration of various models based on customer needs [64][66] - **Implementation Challenges**: New AI product deployments are taking longer due to the complexity of integration compared to previous seat-based models [69] This summary encapsulates the key insights from the Five9 FY Conference, highlighting the company's growth trajectory, leadership changes, competitive advantages, and financial outlook.